Robert Riley, MD
Interventional Cardiology · Bellevue, WANPI 1518123991
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.7%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Shockwave Medical, Inc accounts for 60.7% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2021 at $99,441 and has fallen 78.3% since, to $21,601 in 2025. Among interventional cardiology clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 409 payments — averaging $1054.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Shockwave Medical, Inc$262K
- Boston Scientific$107K
- Medtronic$29K
- Abbott$16K
- Asahi Intecc USA, Inc.$11K
- Abiomed$4K
- plus $2K from 13 others
Across 51 payments — averaging $4333.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Shockwave Medical, Inc$173K
- Boston Scientific$48K
What the payments were for
- Consulting fees$180,52542%
- Speaking & faculty fees$218,55951%
- Grants$9040%
- Travel & lodging$12,4333%
- Food & beverage$18,7484%
- Education$650%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Shockwave Medical, Inc | 152 | $261,819 |
| Boston Scientific | 146 | $106,537 |
| Medtronic(2 entities) | 30 | $29,389 |
| Abbott | 24 | $16,176 |
| Asahi Intecc USA, Inc. | 17 | $10,973 |
| Abiomed | 16 | $4,397 |
| Siemens Medical Solutions USA, Inc. | 4 | $402 |
| Asahi Intecc CO., LTD. | 2 | $337 |
| Teleflex LLC | 3 | $299 |
| Corindus Inc. | 2 | $212 |
| Terumo Medical Corporation | 1 | $156 |
| Biotronik Inc. | 1 | $138 |
| Inari Medical, Inc. | 3 | $137 |
| Philips North America LLC | 1 | $107 |
| Johnson & Johnson | 2 | $44 |
| Edwards Lifesciences | 1 | $37 |
| AstraZeneca | 2 | $32 |
| Pfizer | 1 | $27 |
| Chiesi USA, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$179,146
- Vascular Lithotripsy$81,202
- GENERAL VASCULAR ACCESS$30,942
- Resolute$27,992
- Dragonfly OCT$14,500
- CROSSBOSS$13,265
- ROTABLATOR$7,493
- ASAHI PTCA Guide Wire$7,100
- SYNERGY$5,750
- Watchman$5,300
- GENERAL - THERAPIES$4,764
- Impella$4,157
- STINGRAY$3,265
- OPTICROSS$2,737
- GENERAL ATHERECTOMY$2,163
- ASAHI Corsair Pro Microcatheter XS$2,000
- WOLVERINE$1,500
- ASAHI PTCA Guide Wire Minamo$1,500
- GENERAL - STENTS$1,269
- Xience V coronary stent system$1,146
How this compares
$431,234 in reported general payments places this provider in the 95th percentile of 125 interventional cardiology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 74 | $101,263 |
| EntrestoSacubitril/Valsartan | 22 | $25,977 |
| XareltoRivaroxaban | 14 | $20,172 |
| JardianceEmpagliflozin | 22 | $19,586 |
| Repatha SureclickEvolocumab | 12 | $11,467 |
| Atorvastatin Calcium | 163 | $1,930 |
| ClopidogrelClopidogrel Bisulfate | 160 | $1,588 |
| Metoprolol Succinate | 113 | $1,456 |
| Rosuvastatin Calcium | 57 | $1,071 |
| Carvedilol | 56 | $874 |
| Nifedipine ErNifedipine | 22 | $657 |
| Lisinopril | 61 | $567 |
| Losartan Potassium | 52 | $544 |
| Amlodipine Besylate | 79 | $469 |
| Ezetimibe | 36 | $432 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $27 | $101,26374 claims |
| Johnson & JohnsonXarelto | $44 | $20,17214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 125 interventional cardiology providers in Washington.
Other interventional cardiology in Bellevue
- William LombardiSeattle$902K
- Kathleen KearneySeattle$448K
- Danny DvirSeattle$374K
- James McCabeSeattle$289K
- Christopher BrownSeattle$266K
- Lorenzo AzzaliniSeattle$233K
- Sidakpal PanaichSeattle$214K
- Christine ChungSeattle$210K
- Mohit JainSpokane$98K
- Vishesh KumarVancouver$95K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.